PD-L1 inhibitors have shown efficacy against a variety of cancers, including non-small cell lung cancer (NSCLC), bladder cancer, and melanoma. They are often used when tumors express high levels of PD-L1, or when other treatment options have failed. The list of cancers treated with PD-L1 inhibitors is continually expanding as clinical trials explore their utility in different cancer types.
